Leerink JM, et al. - Researchers analyzed the literature data to evaluate the diagnostic value of biomarkers in detection of late-onset left ventricular (LV) dysfunction in childhood cancer survivors (CCS) treated with anthracyclines more than 1 year since childhood cancer diagnosis. The accepted definitions of LV dysfunction were an ejection fraction < 50% or < 55% and/or a fractional shortening < 28%, < 29% or < 30%. They screened a total of 1,362 original studies, of those, they included eight heterogeneous studies assessing four different biomarkers in mostly asymptomatic CCS. Findings revealed a limited diagnostic value of N-terminal pro-B-type natriuretic peptide for detection of LV dysfunction in CCS in individual studies. With cut-off values as low as 0.01 ng/mL, troponins failed to detect late-onset LV dysfunction.